Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780)

Cancer Research

Volumn 62, Issue 12, 2002, Pages 3428-3437

  Gu, Zhiping ^a   Lee, Richard Y ^a   Skaar, Todd C ^a   Bouker, Kerrie B ^a   Welch, James N ^a   Lu, Jianping ^b   Liu, Aiyi ^a   Zhu, Yuelin ^a   Davis, Natalie ^a   Leonessa, Fabio ^a   Brünner, Nils ^c   Wang, Yue ^b   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b The Catholic University of America ^*  (United States)

^c FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; FULVESTRANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; NUCLEOPHOSMIN; PARTHENOLIDE; TRANSCRIPTION FACTOR;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP RESPONSIVE ELEMENT; DNA MICROARRAY; DRUG EXPOSURE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HORMONAL REGULATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; BREAST NEOPLASMS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-1; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NF-KAPPA B; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 18544396176     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Acquired estrogen independence and antiestrogen resistance in breast cancer: Estrogen receptor-driven phenotypes?
2. Cellular and molecular pharmacology of antiestrogen action and resistance
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
5. Pharmacokinetics, pharmacological and anti-tumor effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
6. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
7. Human breast cancer in athymic nude mice: Cytostatic effects of long-term antiestrogen therapy
8. Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer
9. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells
10. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast career variant which retains sensitivity to the steroidal antiestrogen ICl 182, 780
11. MCF7/LCC9: An antiestrogen resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early cross-resistance to the non-steroidal antiestrogen tamoxifen
12. DNA arrays reveal cancer in its many forms
13. Molecular portraits of human breast tumours
14. Systematic variation in gene expression patterns in human cancer cell lines
15. In vivo gene expression profile analysis of human breast cancer progression
16. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance
17. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications
18. Effect of estradiol on human breast cancer cells in culture
19. Serial analysis of gene expression
20. Small changes in expression affect predisposition to tumorigenesis
21. Wang comparing statistical tests for SAGE experiments
22. Antibodies
23. Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells
24. Amino acid sequence of a specific antigenic peptide of protein B23
25. A method for quantification and correction of proteins after transfer to immobilization membranes
26. The effects of a constitutive production of TGF-α on the growth of MCF-7 human breast cancer cells in vitro and in vivo
27. Experimental models for the study of human cancer cell invasion and metastasis
28. Iterative normalization of cDNA microarray data
29. Elevated Egr-I in human atherosclerotic cells transcriptionally represses the transforming growth factor-β type II receptor
30. Searching for evidence of altered gene expression: A comment on statistical analysis of microarray data
31. Data management and analysis for gene expression arrays
32. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
33. Optimal grid-clustering: Towards breaking the curse of dimensionality in high-dimensional clustering
34. Discriminative mining of gene microarray data
35. Probabilistic principal component subspaces: A hierarchical finite mixture model for data visualization
36. Data mapping by probabilistic modular networks and information theoretic criteria
37. Gene-expression profiles in hereditary breast cancer
38. Autoantibodies to numatrin: An early predictor for relapse in breast cancer
39. The basic domain/leucine zipper protein hXBP-1 preferentially binds to and transactivates CRE-like sequences containing an ACGT core
40. In situ hybridization studies suggest a role for the basic region-leucine zipper protein hXBP-1 in exocrine gland and skeletal development during mouse embryogenesis
41. Predicting the clinical status of human breast cancer by using gene expression profiles
42. The invasive and metastatic properties of hormone-independent and hormone-responsive variants of MCF-7 human breast cancer cells
43. Alterations and role of human cathepsin D in cancer metastasis
44. Heat shock protein (HSP)27: A further refinement in the diagnosis of suspicious fine needle aspirates of breast
45. Expression of vitamin B12 R-binder in breast tumors. An immunohistochemical study
46. A prospective study on folate. B12, and pyridoxal 5′-phosphate (B6) and breast cancer
47. Aberrant function of the Ras signal transduction pathway in human breast cancer
48. Cytosol and serum ferritin in breast carcinoma
49. Bootstrapping cluster analysis: Assessing the reliability of conclusions from microarray experiments
50. Characterization of variability in large-scale gene expression data: Implications for study design
51. Epidermal growth factor gene expression in human breast cancer biopsy samples: Relationship to estrogen and progesterone receptor gene expression
52. The egr-1 gene is induced by epidermal growth factor in ECV304 cells and primary endothelial cells
53. Ionizing radiation down-regulates p53 protein in primary Egr-I-/- mouse embryonic fibroblast cells causing enhanced resistance to apoptosis
54. Inhibition of the RelA(p65) NF-κB subunit by Egr-I
55. Decreased Egr-I expression in human, mouse and rat mammary cells and tissues correlates with tumor formation
56. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1
57. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage
58. Induction of transcription factor interferon regulatory factor-1 by interferon-γ (IFN γ) and tumor necrosis factor-α (TNF α) in FRTL-5 cells
59. Differences in susceptibility to tumor necrosis factor α-induced apoptosis among MCF-7 breast cancer cell variants
60. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells
61. Serum concentration of tumor necrosis factor in patients with breast cancer
62. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway
63. Human breast cancer cross-resistance to TNF and adriamycin: Relationship to MDRI. Mn-SOD and TNF gene expression
64. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo
65. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth
66. Watson apoptosis in mammary epithelial cells
67. Differential regulation of AP1 activity by retinoic acid in hormone-dependent and -independent breast cancer cells
68. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex
69. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide
70. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones
71. Transcription factors IRF-1 and IRF-2: Linking the immune responses and tumor suppression
72. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes
73. IFN-β induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7
74. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix
75. Fas expression and function in normal and malignant breast cell lines
76. Interferon regulatory factor-1 (IRF-1) in breast cancer
77. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity
78. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
79. Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells
80. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
81. 6-Hydroxydopamine-induced nuclear factor-κ B activation in PC12 cells
82. Involvement of nuclear factor-κ B (NF-κB) activation in mitogen-induced lymphocyte proliferation: Inhibitory effects of lymphoproliferation by salicylates acting as NF-κB inhibitors
83. Cyclic AMP response element binding proteins: A cornucopia of transcription factors
84. Signal transduction and gene control: The cAMP pathway
85. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: A comparison of the effects of cyclic adenosine 3′, 5′-monophosphate, estradiol, insulin-like growth factor-1, and serum factors
86. CRE-transcription factor decoy oligonucleotide inhibition of MCF-7 breast cancer cells: Cross-talk with p53 signaling pathway
87. Ozato interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression
88. Endothelial interferon regulatory factor 1 cooperates with NF-κ B as a transcriptional activator of vascular cell adhesion molecule 1
89. Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2
90. Structure of IRF-1 bound DNA reveals determinants of interferon regulation
91. Tumor necrosis factor-α and interferon-γ synergistically activate the RANTES promoter through nuclear factor κB and interferon regulatory factor I (IRF-1) transcription factors
92. Triggering of the human interleukin-6 gene by interferon-γ and tumor necrosis factor-α in monocytic cells involves cooperation between interferon regulatory factor-1, NFκB, and SPI transcription factors
93. The mechanism of transcriptional synergy of an in vitro assembled interferon-β enhanceosome
94. Recombinant human interferon α increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effects of tamoxifen
95. Effects of tamoxifen and interferon-β or the combination on tumor-induced angiogenesis
96. Natural interferon-β and tamoxifen in hormone-resistant patients with advanced breast cancer
97. Vasointestinal polypeptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NFκB and IFN regulatory factor 1 activation
98. Hormonal aspects of breast cancer: Growth factors, drugs and stromal interactions